Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03902080 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
A Phase 3 study, sponsored by Urovant Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,105
- Enrollment target
NCT03902080 is a Phase 3 study that has completed, run by Urovant Sciences. The registered enrollment target is 1,105 participants.
The verdict
NCT03902080, a Phase 3 study, has completed, sponsored by Urovant Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,105 participants
- Enrollment target
Study Summary
This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.
Interventions
- DRUG Placebo
- DRUG Vibegron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,105 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2023-06-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03902080
The ClinicalTrials.gov registry entry for NCT03902080 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Urovant Sciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03902080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03902080 about?
NCT03902080 is a clinical study titled "Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)". This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.
What is the current status of trial NCT03902080?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,105 participants. The study started on 2019-03-26. Estimated completion is 2023-06-15.
What interventions are being tested in trial NCT03902080?
The interventions under investigation include: Placebo (DRUG), Vibegron (DRUG).
Who is sponsoring clinical trial NCT03902080?
This trial is sponsored by Urovant Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.